Mr. George Achilleos reports

NETRAMARK STRENGTHENS BOARD OF DIRECTORS

Lawrence Guy is joining Netramark Holdings Inc.'s board of directors.

Mr. Guy's appointment further strengthens the board with his deep experience in capital markets, investment management and public-company governance.

Mr. Guy is currently a managing director with Next Edge Capital, an investment fund manager, where he focuses on strategic partnerships, corporate initiatives and the evaluation of new investment opportunities. He brings extensive experience in financial leadership, fund management, and corporate development across both private and public markets.

Prior to Next Edge Capital, Mr. Guy served as a vice-president at Purpose Investments, where he joined the firm at an early stage and contributed to its significant growth. Earlier in his career, he was a portfolio manager at Aston Hill Financial Inc. Before that, Mr. Guy was the chief financial officer and a director of Navina Asset Management Inc., a firm he co-founded that was subsequently acquired by Aston Hill Financial Inc.

Mr. Guy holds a BA (economics) from the University of Western Ontario and is a chartered financial analyst.

Currently, he is a director of Emerita Resources Corp., Lithium Ionic Corp., Nobel Resources Corp. and Halcones Precious Metals Corp.

"We are pleased to welcome Larry to Netramark's board or directors," said George Achilleos, chief executive officer of Netramark. "We believe that his breadth of experience across investment management, corporate finance and board governance will be highly valuable as we continue to advance our strategy and scale the company's operations."

About Netramark Holdings Inc.

Netramark is a company focused on being a leader in the development of generative artificial intelligence (Gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent information that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.